Table 1.
Patient characteristics by study arm
| Fulvestrant | Fulvestrant + Everolimus | Fulvestrant + Everolimus + Anastrozole | ||||
|---|---|---|---|---|---|---|
| (n=13) | (n=12) | (n=12) | ||||
| AGE | ||||||
| Median | 63.4 | 62.6 | 60.5 | |||
| Minimum | 54 | 45 | 48 | |||
| Maximum | 74 | 87 | 69 | |||
| HISPANIC | ||||||
| Yes | 1 | 8% | 2 | 17% | 0 | 0% |
| No | 12 | 92% | 10 | 83% | 12 | 100% |
| RACE | ||||||
| White | 9 | 69% | 10 | 83% | 9 | 75% |
| Black | 2 | 15% | 0 | 0% | 3 | 25% |
| Asian | 0 | 0% | 1 | 8% | 0 | 0% |
| Multi-Racial | 1 | 8% | 0 | 0% | 0 | 0% |
| Unknown | 1 | 8% | 1 | 8% | 0 | 0% |
| DISEASE | ||||||
| Measurable | 9 | 69% | 10 | 83% | 9 | 75% |
| Evaluable non-measurable disease | 4 | 31% | 2 | 17% | 3 | 25% |
| PRIOR HORMONE | ||||||
| Prior adjuvant hormonal therapy completed more than 5 years ago | 3 | 23% | 1 | 8% | 2 | 17% |
| Prior adjuvant hormonal therapy completed 1–5 years ago | 4 | 31% | 5 | 42% | 6 | 50% |
| De novo presentation of metastatic disease or no prior adjuvant hormonal therapy | 6 | 46% | 6 | 50% | 4 | 33% |